NCT05615974 - A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

January 11, 2023

Primary Completion Date

January 11, 2027

Study Completion Date

January 11, 2028

Conditions

Malignant Tumors

Interventions

DRUG

LM101

Administered intravenously

DRUG

Toripalimab

Administered intravenously

DRUG

Rituximab

Administered intravenously

Trial Locations (5)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

NOT_YET_RECRUITING

Linyi Cancer Hospital, Linyi

TERMINATED

Beijing Tongren Hospital, CMU, Beijing

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai